---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-107339"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:21:31.399420+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint

## Summary
- Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.
- Cash $29.8M at June 30, 2025; $5.0M gross financing extends runway into Q3 2026.
- ENLIGHTEN 2 Phase 3 met primary endpoint: 3CS improvement -1.13 (p=0.0078) at week 24; key secondary endpoints also met.
- Preparing for Type C meeting with FDA in H2 2025 to align on NDA submission path for LYR-210 in CRS without nasal polyps.
- Completed 1-for-50 reverse stock split in May; regained Nasdaq minimum bid compliance.

## SEC filing metadata
- accession: 0000950170-25-107339
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/0000950170-25-107339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/lyra-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-107339
- JSON: https://secwatch.observer/filing/0000950170-25-107339.json
- Plain text: https://secwatch.observer/filing/0000950170-25-107339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.